YK012 for injection is an innovative drug of biological products designed with the concept of Quality by Design and developed based on the FIST platform owned by Ecotech. YK012, which targets CD3 and CD19 at the same time, is a new generation of safe, high-yield, long-acting and low-cost bispecific antibody drugs for the treatment of non-Hodgkin's lymphoma (NHL). Pre-clinical research data show that YK012 mildly activates immune cells and can avoid T-cell failure. Compared with similar products, the release of cytokines is significantly reduced, which is expected to significantly improve its clinical safety. The expression of YK012 is high, the production process is mature and stable, it is easy to realize industrialization, and the production cost is low. It is expected that the treatment cost will be greatly reduced and the economic burden of patients will be reduced after the market. The structural characteristics of YK012 make it have a long half-life similar to that of traditional monoclonal antibodies, so it is expected to be used once every two weeks in clinical practice, which is convenient for patients.
In 2022, YK012 for injection has obtained the clinical trial license of the State Drug Administration. In 2023, the phase I clinical trial of YK012 for injection has been started.